Risk of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Among Patients with Type 2 Diabetes Mellitus on Anti-Hyperglycemic Medications

References

• Cutler DM. The Costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809–e221809. doi:10.1001/jamahealthforum.2022.1809
   PubMedGoogle Scholar
• Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461–1467. doi:10.1038/s41591-022-01840-0
   PubMed Web of Science ®Google Scholar
• Ayoubkhani D, Bosworth ML, King S, et al. Risk of Long COVID in people infected with severe acute respiratory syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: community-based, matched cohort study. Open Forum Infect Dis. 2022;9(9). doi:10.1093/ofid/ofac464
   PubMed Web of Science ®Google Scholar
• Simon MA, Luginbuhl RD, Parker R. Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 diagnosis and up to 12 weeks after. medRxiv. 2021;2021:21263608.
   Google Scholar
• Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nature Med. 2022;28(8):1706–1714. doi:10.1038/s41591-022-01909-w
   PubMed Web of Science ®Google Scholar
• Groff D, Sun A, Ssentongo AE, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: a Systematic Review. JAMA Net Open. 2021;4(10):e2128568–e2128568. doi:10.1001/jamanetworkopen.2021.28568
   PubMed Web of Science ®Google Scholar
• Aiyegbusi OL, Hughes SE, Turner G, et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114(9):428–442. doi:10.1177/01410768211032850
   PubMed Web of Science ®Google Scholar
• Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific Rep. 2021;11(1):1–12.
   PubMedGoogle Scholar
• Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–264. doi:10.1038/s41586-021-03553-9
   PubMed Web of Science ®Google Scholar
• Brannock MD, Chew RF, Preiss AJ, et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nature Commun. 2023;14(1):1–12.
   PubMed Web of Science ®Google Scholar
• Wu Q, Ailshire JA, Crimmins EM, Mitrosz P, Szakiel J, Turek P. Long COVID and symptom trajectory in a representative sample of Americans in the first year of the pandemic. Sci Rep. 2022;12(1):1–11. doi:10.1038/s41598-021-99269-x
   PubMed Web of Science ®Google Scholar
• Wong R, Hall M, Vaddavalli R, et al. Glycemic control and clinical outcomes in U.S. Patients With COVID-19: data From the National COVID Cohort Collaborative (N3C) Database. Diab Care. 2022;45(5):1099. doi:10.2337/dc21-2186
   PubMed Web of Science ®Google Scholar
• Nassar M, Daoud A, Nso N, et al. Diabetes Mellitus and COVID-19: Review Article. Diabetes Metab Syndr. 2021;15(6):102268. doi:10.1016/j.dsx.2021.102268
   PubMed Web of Science ®Google Scholar
• Wong R, Lam E, Bramante CT, et al. Does COVID-19 Infection Increase the Risk of Diabetes? Curr Evid Curr Diab Rep. 2023;23(8):207–216. doi:10.1007/s11892-023-01515-1
   PubMed Web of Science ®Google Scholar
• Khunti K, Prato SD, Mathieu C, Kahn SE, Gabbay RA, Buse JB. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care. 2021;44(12):2645–2655. doi:10.2337/dc21-1318
   PubMed Web of Science ®Google Scholar
• Rizvi AA, Kathuria A, Al Mahmeed W, et al. Post-COVID syndrome, inflammation, and diabetes. J Diabetes Complicat. 2022;36(11):108336. doi:10.1016/j.jdiacomp.2022.108336
   PubMed Web of Science ®Google Scholar
• Xian H, Liu Y, Rundberg Nilsson A, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54(7):1463–1477.e11. doi:10.1016/j.immuni.2021.05.004
   PubMed Web of Science ®Google Scholar
• Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res. 2023;323:199010. doi:10.1016/j.virusres.2022.199010
   PubMed Web of Science ®Google Scholar
• Ventura-López C, Cervantes-Luevano K, Aguirre-Sánchez JS, et al. Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in vitro model and randomized, double-blind, Phase IIb clinical trial. Biomed Pharm. 2022;152:113223. doi:10.1016/j.biopha.2022.113223
   PubMed Web of Science ®Google Scholar
• Bramante CT, Beckman B. Metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial. medRxiv. 2023;2023(06):23290989.
   Google Scholar
• Bramante CT, Buse JB, Liebovitz DM, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119–1129. doi:10.1016/S1473-3099(23)00299-2
   PubMed Web of Science ®Google Scholar
• Erickson SM, Fenno SL, Barzilai N, et al. Metformin for Treatment of Acute COVID-19: Systematic review of clinical trial data against SARS-CoV-2. Diabetes Care. 2023;46(7):1432–1442. doi:10.2337/dc22-2539
   PubMed Web of Science ®Google Scholar
• MCCarthy MW. Metformin as a potential treatment for COVID-19. Expert Opin Pharm. 2023;24(10):1199–1203. doi:10.1080/14656566.2023.2215385
   PubMed Web of Science ®Google Scholar
• Bramante CT, Johnson SG, Garcia V, et al. Diabetes medications and associations with Covid-19 outcomes in the N3C database: a national retrospective cohort study. PLoS One. 2022;17(11):e0271574. doi:10.1371/journal.pone.0271574
   PubMed Web of Science ®Google Scholar
• Parotto M, Gyöngyösi M, Howe K, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med. 2023;11(8):739–754. doi:10.1016/S2213-2600(23)00239-4
   PubMed Web of Science ®Google Scholar
• Tandon P, Abrams ND, Avula LR, et al. Unraveling Links between Chronic Inflammation and Long COVID: workshop report. J Immunol. 2024;212(4):505–512. doi:10.4049/jimmunol.2300804
   PubMed Web of Science ®Google Scholar
• Chan LE, Casiraghi E, Laraway B, et al. Metformin is associated with reduced COVID-19 severity in patients with prediabetes. Diabet Res Clin Pract. 2022;194:110157. doi:10.1016/j.diabres.2022.110157
   PubMed Web of Science ®Google Scholar
• Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. J Am Med Inform Assoc. 2021;28(3):427–443. doi:10.1093/jamia/ocaa196
   PubMed Web of Science ®Google Scholar
• Pfaff ER, Girvin AT, Bennett TD, et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022;4(7):e532–e541. doi:10.1016/S2589-7500(22)00048-6
   PubMedGoogle Scholar
• Hainmueller J. Entropy balancing for causal effects: A Multivariate reweighting method to produce balanced samples in observational studies. Political Anal. 2012;20(1):25–46. doi:10.1093/pan/mpr025
   Web of Science ®Google Scholar
• Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022;387(7):599–610. doi:10.1056/NEJMoa2201662
   PubMed Web of Science ®Google Scholar
• Brand KMG, Saarelainen L, Sonajalg J, et al. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. BMJ Open Diabetes Res Care. 2022;10(1):e002363. doi:10.1136/bmjdrc-2021-002363
   PubMed Web of Science ®Google Scholar
• Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8(10):834–844. doi:10.1016/S2213-8587(20)30310-7
   PubMed Web of Science ®Google Scholar
• Soliman A, De Sanctis V, Alaaraj N, Hamed N. The clinical application of metformin in children and adolescents: a short update. Acta Bio Medica. 2020;91(3).
   Google Scholar
• A clinical case definition of post COVID-19 condition by a Delphi consensus; 2021.
   Google Scholar
• Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934–1946. doi:10.1001/jama.2023.8823
   PubMed Web of Science ®Google Scholar
• Khullar D, Zhang Y, Zang C, et al. Racial/Ethnic Disparities in Post-acute Sequelae of SARS-CoV-2 Infection in New York: an EHR-Based Cohort Study from the RECOVER Program. J Gen Intern Med. 2023;38(5):1127–1136. doi:10.1007/s11606-022-07997-1
   PubMed Web of Science ®Google Scholar
• Lopez L, Hart LH, Katz MH. Racial and Ethnic Health Disparities Related to COVID-19. JAMA. 2021;325(8):719–720. doi:10.1001/jama.2020.26443
   PubMed Web of Science ®Google Scholar
• Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol. 2003;158(9):915–920. doi:10.1093/aje/kwg231
   PubMed Web of Science ®Google Scholar
• Joshua Lin K, Jin Y, Gagne J, et al. Longitudinal data discontinuity in electronic health records and consequences for medication effectiveness studies. Clin Pharmacol Ther. 2022;111(1):243–251. doi:10.1002/cpt.2400
   PubMed Web of Science ®Google Scholar